Arcutis Biotherapeutics, Inc. (Nasdaq: Arqt) company information, Employees & Contact Information

Arcutis (Nasdaq: ARQT) to present at Guggenheim, TD Cowen; webcasts with 180-day replay Stock Titan

Arcutis to Present at Upcoming Investor Conferences MarketScreener

Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results The Manila Times

Pipeline Updates on the Horizon From Arcutis Biotherapeutics Dermatology Times

Arcutis Announces Chief Financial Officer Transition Yahoo Finance

Arcutis Biotherapeutics Announces FDA Approval of ZORYVE® Cream 0.05% for Treatment of Atopic Dermatitis in Children Aged 2 to 5 Quiver Quantitative

Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award GlobeNewswire

Arcutis: Leveraging Zoryve’s Success While Positioning For Pipeline Expansion (ARQT) Seeking Alpha

94,500 RSUs Granted — Arcutis Reports Inducement Grants to 12 New Hires, Vesting Over Four Years Stock Titan

Arcutis Biotherapeutics Submits Application for ZORYVE Cream as First Topical Treatment for Plaque Psoriasis in Children Ages 2 and Up Quiver Quantitative

Dermatology Leader Arcutis Announces Strategic Growth Plan Reveal at October Investor Day Stock Titan

35,500 Restricted Stock Units: Arcutis Biotherapeutics Grants Equity Awards to New Immuno-Dermatology Team Stock Titan

Immuno-Dermatology Leader Arcutis Lines Up Triple Conference Presence: Citi, Morgan Stanley & HC Wainwright Stock Titan

79.5% Success Rate: Arcutis' ZORYVE Foam Proves Highly Effective for Seborrheic Dermatitis Across All Skin Types Stock Titan

#1 Prescribed Dermatology Treatment ZORYVE Wins Prestigious Allure Award for Revolutionary Skin Care Stock Titan

Arcutis Reports Massive 164% Revenue Jump, Hits 1M Prescriptions and Wins FDA Approval Stock Titan

Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older Sahm

Arcutis Biotherapeutics Reports Positive Phase 3 Study Results for Investigational ZORYVE Foam 0.3% in Treating Scalp and Body Psoriasis Quiver Quantitative

Arcutis Q1 Earnings: ZORYVE Sales Surge 196% to $64M as Coverage Expands | ARQT Stock News Stock Titan

First-Ever PDE4 Inhibitor for Toddlers: Arcutis' ZORYVE Aims to Transform Psoriasis Treatment Ages 2-5 Stock Titan

Arcutis Biotherapeutics to Present New Data on ZORYVE® for Atopic Dermatitis and Psoriasis at 2025 AAD Annual Meeting Quiver Quantitative

Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a “Clear Win for Your Skin” MultiVu

Patricia Turney Joins Arcutis as Senior Vice President, Manufacturing ACCESS Newswire

Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older National Eczema Association

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update FinancialContent

Arcutis Submits sNDA for Roflumilast Cream 0.3% for Psoriasis in Children Aged 2-5 Years HCPLive

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age National Eczema Association

Arcutis’ Roflumilast Becomes First FDA-Approved Treatment to Receive the NPF’s Seal of Recognition Dermatology Times

FDA Accepts Supplemental New Drug Application for Arcutis’ Roflumilast in Children with AD Dermatology Times

Arcutis Biotherapeutics Reports New Phase 3 Data on ZORYVE Cream Demonstrating Reduced Sleep Disruptions and Long-Term Disease Control in Atopic Dermatitis Patients Quiver Quantitative

Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc. GlobeNewswire

Arcutis Enrolls Last Participant in ARQ-255 Trial for AA Dermatology Times

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older National Eczema Association

Arcutis Appoints Latha Vairavan as Chief Financial Officer citybiz

Roflumilast Cream 0.15% Launched by Arcutis for the Treatment of Eczema HCPLive

In Japan, Arcutis and Sato Enter Strategic Collaboration and Licensing Agreement for Topical Roflumilast Dermatology Times

Understanding Roflumilast Foam's FDA Approval for Scalp and Body Psoriasis, with Jennifer Soung, MD HCPLive

Arcutis’ Zoryve Shows Progress for Individuals with Atopic, Seborrheic Dermatitis Pharmaceutical Executive

Arcutis (NASDAQ: ARQT): ZORYVE 63.1% vIGA-AD clear or almost clear at 56 weeks Stock Titan

Zoryve Cream 0.15% for Atopic Dermatitis Now Available Medical Professionals Reference

NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEING PR Newswire

Health Canada Approves Roflumilast Foam 0.3% for Patients 9 Years and Older With Seborrheic Dermatitis Dermatology Times

FDA Accepts Roflumilast Foam sNDA for Scalp and Body Psoriasis Dermatology Times

Arcutis' ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour The Manila Times

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) The Manila Times

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age Stock Titan

FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6 Stock Titan

NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, ME MultiVu

Arcutis Biotherapeutics to Terminate Phase 2a Vitiligo Study Dermatology Times

Arcutis Announces Arcutis Cares™ Patient Assistance Program (PAP) For Financially Qualified Uninsured and Underinsured Patients Stock Titan

NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEING Stock Titan

Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference The Manila Times

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age PR Newswire Canada

Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older PR Newswire Canada

Arcutis Biotherapeutics Reaches Regulatory Milestone with Health Canada Acceptance of New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis PR Newswire Canada

Arcutis Canada Submission for Roflumilast Cream 0.15% Accepted for Review by Health Canada for the Treatment of Atopic Dermatitis in Adults and Children 6 Years of Age and Older PR Newswire Canada

Arcutis Biotherapeutics Inc (ARQT) Stock Price, Trades & News GuruFocus

ARQT Stock Price and Chart — NASDAQ:ARQT TradingView

Arcutis Biotherapeutics Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Phase 3 Program for ARQ-151 for Plaque Psoriasis ACCESS Newswire